Bristol-Myers Squibb (BMY) Hisse Özeti
Bristol-Myers Squibb Company biyofarmasötik ürünleri keşfeder, geliştirir, lisanslar, üretir, pazarlar, dağıtır ve dünya çapında satar. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 5/6 |
Ödüller
Risk Analizi
Last Earnings Call
Q2 2026 · 30 Jul 2026Bristol-Myers Squibb (BMS) reported a strong Q2 2026, with revenue of $13 billion, a 5% year-over-year increase. The growth portfolio—featuring key assets like Reblozyl, Breyanzi, and Camzyos—rose 14%, now accounting for nearly 60% of total revenue. Eliquis remained a standout, with 21% growth. Due to this first-half momentum, management raised full-year 2026 revenue and adjusted EPS guidance.
Analyst Consensus vs. Actual Results:
- Revenue: Consensus estimates were approximately $12.75 billion. BMS beat expectations with $13 billion.
- Adjusted EPS: Consensus estimates were $1.98. BMS beat expectations with $2.04.
Management emphasized continued investment in its CELMoD platform (iberdomide, mezigdomide) and highlighted progress in its pipeline, though they noted timing updates for milvexian and the Cobenfy ADEPT program, now expected to read out in 2027.
Market Reaction
Bristol-Myers Squibb’s stock rose by approximately 3.2% on July 30, 2026. Analysts cited the earnings beat, the raised full-year financial guidance, and the robust 14% growth in the company's core "growth portfolio" as primary drivers for the positive investor sentiment.
BMY Community Fair Values
Create NarrativeSee what 359 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Bristol-Myers Squibb Company Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$66.05 |
| 52 Haftanın En Yüksek Seviyesi | US$68.10 |
| 52 Haftanın En Düşük Seviyesi | US$42.52 |
| Beta | 0.23 |
| 1 Aylık Değişim | 8.74% |
| 3 Aylık Değişim | 12.83% |
| 1 Yıllık Değişim | 36.64% |
| 3 Yıllık Değişim | 6.77% |
| 5 Yıllık Değişim | -3.60% |
| Halka arzdan bu yana değişim | 2,991.19% |
Son Haberler & Güncellemeler
Recent updates
BMY: 2026 Pipeline And M&A Noise Will Not Mitigate Patent Cliff
Analysts have lifted their blended price targets for Bristol-Myers Squibb toward the $70 to $75 range, citing improving sentiment around growth products, recent Q2 earnings updates, and ongoing debate around potential M&A interest as key drivers behind the reassessment of fair value from about $45.67 to roughly $49.02 per share. Analyst Commentary Recent research coverage on Bristol-Myers Squibb highlights a mix of improving sentiment and lingering concerns.Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Bristol-Myers Squibb Company ( NYSE:BMY ) investors will be delighted, with the company turning in some strong numbers...
BMY: Q2 Execution And Late Stage Pipeline Will Drive Re Rating
Analysts have lifted the fair value estimate for Bristol-Myers Squibb to $80 from $75, citing recent price target increases into the low to mid $70s and a consistent focus on the company's Q2 results and pipeline potential as key factors supporting the updated view. Analyst Commentary Recent Street research on Bristol-Myers Squibb highlights a cluster of higher price targets following Q2 results.Bristol Myers Squibb: Upgrading To Buy On Positive Q2 Earnings, Long-Term Outlook
Summary Bristol Myers Squibb delivered strong Q2 2026 results, with revenue and EPS both exceeding expectations and robust cash flow performance. BMY’s forward P/E of ~9.2x and P/S of ~2.6x, combined with a ~4% dividend yield, suggest the stock is undervalued versus Big Pharma peers. While legacy portfolio revenues decline due to patent expiries, the growth portfolio is gaining traction, though some assets have underperformed expectations. I upgrade BMY to Buy, citing a promising late-stage pipeline and confidence that new launches will offset Eliquis’s eventual revenue loss. Read the full article on Seeking AlphaBMY: Late Stage Pipeline Wins And Policy Risks Will Drive Re Rating
Analysts slightly revised their average price target for Bristol-Myers Squibb stock, reflecting updated views on a modestly softer revenue outlook, stable fair value near $75.00, and largely unchanged long term margin and P/E assumptions following recent commentary on Medicare negotiation risk. Analyst Commentary Bristol-Myers Squibb continues to attract mixed but constructive attention from Wall Street, with recent notes focusing on Medicare negotiation risk, price target fine-tuning, and how current valuation lines up with long term earnings power.Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion
Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, adding new casdatifan arms to the ROSETTA RCC-208 study. See our latest analysis for Bristol-Myers Squibb. The kidney cancer trial expansion comes after a mixed period for Bristol-Myers Squibb, with the share price at $56.24, a year to date share price return of 5.2%, and a 1 year total shareholder return of 21.35%. This suggests...BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating
Analysts have raised the average Bristol-Myers Squibb price target by a few dollars, citing a series of recent upward revisions into the $60 to $70 range. These revisions reflect ongoing debate around macro risks, healthcare sector positioning, and upcoming Milvexian Phase III data.
BMY: Pipeline Execution And Macro Shifts Will Shape Future Risk Balance
Analysts now see Bristol-Myers Squibb’s fair value edging down by $0.08 to $62.96, as they factor in slightly weaker revenue growth and profit margin assumptions alongside a higher future P/E, even as recent Street price target moves reflect mixed views on the stock’s pipeline and macro setup. Analyst Commentary Recent Street commentary on Bristol-Myers Squibb highlights a wide range of views on execution risk, pipeline delivery and how those factors may feed into valuation over the next few years.BMY: Upcoming Late Stage Readouts Will Drive Potential Re Rating Opportunity
Analysts have made only a modest adjustment to their Bristol-Myers Squibb outlook, with small changes to revenue and profitability assumptions feeding into updated price targets that cluster in a wide range from about $60 to $75. This reflects differing views on the pipeline and upcoming Milvexian data as potential drivers for the story.BMY: Pipeline Progress And Sector Shifts Will Shape Future Risk Balance
Analysts have raised the implied fair value for Bristol-Myers Squibb to $63.04 from $59.91, reflecting a series of recent price target increases based on slightly less severe revenue contraction expectations, a modest improvement in projected profit margins, and support from pipeline-related research updates across multiple firms. Analyst Commentary Recent research has focused on how Bristol-Myers Squibb balances patent expirations on key products with progress in its pipeline and late stage programs, and how that mix feeds into valuation, execution risk, and potential growth beyond current revenue headwinds.BMY: 2026 Catalyst Calendar Will Likely Fail To Offset Patent Cliff
Analyst price targets for Bristol-Myers Squibb have moved higher into a broad $60 to $75 range, with analysts pointing to a rich 2026 catalyst calendar, emerging pipeline readouts such as milvexian Phase III data, and relatively lower exposure to AI disruption risks as key supports for the updated views. Analyst Commentary Recent research highlights a mix of optimism and caution around Bristol-Myers Squibb, with the Street focusing on a packed 2026 catalyst calendar, milvexian Phase III data, and a broad set of late stage assets.BMY: 2026 Late Stage Pipeline Catalysts Will Likely Limit Further Upside
The analyst price target for Bristol Myers Squibb has moved higher, with the fair value estimate shifting from $40.67 to $45.67 as analysts point to a richer pipeline of late stage catalysts, a higher projected profit margin, and sector wide support from the appeal of healthcare during a choppy macro backdrop. Analyst Commentary Recent research coverage on Bristol Myers Squibb has tilted more constructive, with several firms lifting price targets into the US$60 to US$75 range and highlighting a dense calendar of late stage readouts through 2026.BMY: 2026 Late-Stage Pipeline Readouts Will Shape Re-Rating Potential
Analysts have lifted their Bristol Myers Squibb fair value estimate from $68.00 to $75.00, citing higher Street price targets and an increased focus on pipeline catalysts such as the Phase III milvexian data and a dense slate of 2026 readouts. Analyst Commentary Recent Street research on Bristol Myers Squibb clusters around a more constructive view of the pipeline, especially the 2026 readout slate and the Phase III milvexian program, with several firms revisiting their valuation frameworks in light of these potential catalysts.BMY: 2026 Pipeline Catalysts And Sector Recovery Will Shape Risk Balance
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to about $60. This reflects how recent price target increases and generally constructive research commentary around the pipeline are starting to offset concerns about upcoming patent expirations.We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit
Bristol-Myers Squibb Company ( NYSE:BMY ) announced a healthy earnings result recently, and the market rewarded it with...BMY: 2026 Pipeline Readouts And Sector Recovery Will Guide Next Repricing
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to US$58.13 from US$56.26. This reflects updated Street research in which analysts cite a richer mix of potential 2026 pipeline catalysts and a slightly higher assumed future P/E multiple, both of which support recent price target increases across several firms.BMY: 2026 Pipeline Readouts Will Likely Cap Near Term Upside
Analysts have lifted their blended price target on Bristol Myers Squibb by roughly US$2 to reflect higher estimated fair value and profitability, citing a rich set of 2026 pipeline readouts and what they view as underappreciated upside in several late-stage assets. Analyst Commentary Recent Street research on Bristol Myers Squibb points to a mixed but generally constructive stance, with several firms lifting price targets into the US$53 to US$65 range and highlighting what they see as meaningful 2026 data catalysts across eight late stage assets.BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating
Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.BMY: Sector Perform View Will Limit Upside Despite Upcoming Earnings Focus
Analysts have nudged their fair value estimate for Bristol-Myers Squibb higher to about $38.41 from $35.86, reflecting a modestly richer future earnings multiple despite slightly weaker near term revenue growth and margin assumptions, and a new $45 price target under a Sector Perform view. Analyst Commentary Recent Street commentary frames Bristol-Myers Squibb as a lagging, but not broken, story within large cap biopharma.BMY: Sector Outlook And Policy Shifts Will Shape Next Share Rerating
Analysts have nudged their price target for Bristol-Myers Squibb slightly higher to approximately $54 per share. This reflects a modestly richer future earnings multiple despite expectations for somewhat weaker revenue growth and profit margins, along with a more cautious Sector Perform stance from recent Street research.Aging Demographics And Genomics Will Drive Healthcare Demand
Analysts maintained a cautious outlook on Bristol-Myers Squibb due to muted Cobenfy prescription trends and pipeline execution concerns, partially offset by optimism for upcoming Alzheimer’s data and future optionality, resulting in the consensus price target remaining steady at $53.00. Analyst Commentary Bearish analysts point to recent moderation in Cobenfy prescriptions for schizophrenia and maintain low growth expectations for this indication in the second half of 2025.Hissedar Getirileri
| BMY | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | 3.8% | 2.3% | -0.3% |
| 1Y | 36.6% | 53.6% | 19.9% |
Getiri vs. Endüstri: BMY geçen yıl % 53.6 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: BMY geçen yıl % 19.9 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| BMY volatility | |
|---|---|
| BMY Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: BMY son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: BMY 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1887 | 32,500 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company, dünya çapında biyofarmasötik ürünleri keşfeder, geliştirir, lisanslar, üretir, pazarlar, dağıtır ve satar. Şirket, onkoloji, hematoloji, immünoloji, kardiyovasküler ve nörobilim alanlarında endikasyonlara yönelik ürünler sunmaktadır. Ürünleri arasında kanser tedavisi için Opdivo; solid tümörler için subkutan PD-1 inhibitörü Opdivo Qvantig; aktif romatoid artrit ve psoriatik artrit tedavisi için Orencia; rezeke edilemeyen veya metastatik melanom tedavisi için Yervoy; anemi tedavisi için Reblozyl; nükseden veya refrakter büyük B-hücreli lenfoma tedavisi için Breyanzi; rezeke edilemeyen veya metastatik melanom tedavisi için Opdualag; ve semptomatik obstrüktif HCM tedavisi için Camzyos yer almaktadır.
Bristol-Myers Squibb Company Temel Bilgiler Özeti
| BMY temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$132.02b |
| Kazançlar(TTM) | US$9.28b |
| Gelir(TTM) | US$49.19b |
BMY aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| BMY gelir tablosu (TTM) | |
|---|---|
| Gelir | US$49.19b |
| Gelir Maliyeti | US$13.94b |
| Brüt Kâr | US$35.25b |
| Diğer Giderler | US$25.97b |
| Kazançlar | US$9.28b |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
Oct 29, 2026
| Hisse başına kazanç (EPS) | 4.54 |
| Brüt Marj | 71.66% |
| Net Kâr Marjı | 18.87% |
| Borç/Özkaynak Oranı | 193.2% |
BMY uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/18 04:10 |
| Gün Sonu Hisse Fiyatı | 2026/08/18 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bristol-Myers Squibb Company 45 Bu analistlerden 25, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Charles Butler | Barclays |